| Literature DB >> 28174136 |
Carla Elena Sartori Oliveira1, Marcel Henrique Marcondes Sari1, Vanessa Angonesi Zborowski1, Paulo Cesar Oliveira Araujo1, Cristina Wayne Nogueira1, Gilson Zeni2.
Abstract
Major depressive disorder is the most severe and debilitating disease among psychiatric illnesses. The abrupt interruption of antidepressant treatment may lead to a complex physiological and neuropsychiatric syndrome. The organoselenium compound (MeOPhSe)2 has been reported to have neuroprotective properties in animal models. The study aimed to investigate the effects of single or repeated administration of (MeOPhSe)2 on depressive-like behavior and if the compound administration, and its discontinuation, may affect the anxiolytic-like phenotype in Swiss mice. The results showed that repeated intragastric administration of (MeOPhSe)2 (dose range: 0.1-5mg/kg), different from a single administration, reduced the immobility time in the mouse tail suspension test. A single administration of (MeOPhSe)2 at a dose of 5mg/kg decreased the immobility time, increased the swimming time and did not alter the climbing behavior in the modified forced swimming test (mFST). Repeated administration of (MeOPhSe)2 decreased the immobility time, did not alter the swimming time and increased the climbing behavior in the mouse mFST. Repeated administration of (MeOPhSe)2 at a dose of 5mg/kg elicited a mouse anxiolytic-like phenotype in the elevated plus maze and light-dark tests. Markers of hepatic and renal function tests were not altered by repeated administration of (MeOPhSe)2 to mice. The findings indicate that a single or repeated administration of (MeOPhSe)2 elicited an antidepressant-like action in mice. Moreover, repeated treatment with (MeOPhSe)2 produced an anxiolytic-like action in mice and its profile remained stable after discontinuation.Entities:
Keywords: Antidepressant; Anxiolytic; Discontinuation; Organoselenium; Selenium
Mesh:
Substances:
Year: 2017 PMID: 28174136 DOI: 10.1016/j.pbb.2017.02.002
Source DB: PubMed Journal: Pharmacol Biochem Behav ISSN: 0091-3057 Impact factor: 3.533